Galderma Group N (GALD) - Total Liabilities
Based on the latest financial reports, Galderma Group N (GALD) has total liabilities worth CHF5.15 Billion CHF (≈ $6.51 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore GALD net asset momentum to track the company's year-over-year net asset growth rate.
Galderma Group N - Total Liabilities Trend (2021–2024)
This chart illustrates how Galderma Group N's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Galderma Group N to measure how efficiently the company converts operating cash flow to free cash.
Galderma Group N Competitors by Total Liabilities
The table below lists competitors of Galderma Group N ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Endesa SA
MC:ELE
|
Spain | €30.09 Billion |
|
KOMATSU LTD. SPONS. ADR 1
F:KOMA
|
Germany | €2.54 Trillion |
|
Aselsan Elektronik Sanayi ve Ticaret AS
IS:ASELS
|
Turkey | TL120.03 Billion |
|
Axon Enterprise Inc.
NASDAQ:AXON
|
USA | $3.53 Billion |
|
People's Insurance of China Ltd
SHG:601319
|
China | CN¥1.61 Trillion |
|
Yageo Corp
TW:2327
|
Taiwan | NT$232.60 Billion |
|
Guotai Junan Securities Co Ltd
SHG:601211
|
China | CN¥1.68 Trillion |
|
PT BK CE.AS.ADR/25 RP625
F:BZG
|
Germany | €1305.14 Trillion |
Liability Composition Analysis (2021–2024)
This chart breaks down Galderma Group N's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GALD stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.26 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Galderma Group N's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Galderma Group N (2021–2024)
The table below shows the annual total liabilities of Galderma Group N from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CHF4.83 Billion ≈ $6.10 Billion |
-19.19% |
| 2023-12-31 | CHF5.97 Billion ≈ $7.55 Billion |
-18.75% |
| 2022-12-31 | CHF7.35 Billion ≈ $9.29 Billion |
+0.56% |
| 2021-12-31 | CHF7.31 Billion ≈ $9.24 Billion |
-- |
About Galderma Group N
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epi… Read more